• HTA180 The Value-Generation-Value-Recognition Gap for Novel Gene Therapies in European HTA Systems Using X-Linked Retinitis Pigmentosa as a Case Study

    Dec 1, 2022, 00:00

  • HTA52 Evaluation of Cost by TPS vs Pharmacotherapy of Dementia in Ukraine

    Dec 1, 2022, 00:00

  • EE98 Healthcare Resource Utilization and Costs Associated With Previously Treated Advanced Non-Small Cell Lung Cancer Patients Without EGFR Mutations or ALK Rearrangements in Korea

    Dec 1, 2022, 00:00

  • HTA163 Development of SF-6Dv2 Health Utility Weights in the United States

    Dec 1, 2022, 00:00

  • Patient Heterogeneity and Equity in Stated Preference Studies

    Dec 1, 2022, 00:00

  • EE313 Intensity of Colorectal Cancer Screening Strategies and the Optimal Policy Choi A Systematic Review of European Cost Effectiveness Analyses

    Dec 1, 2022, 00:00

  • HTA268 Impact of Independence and Transparency on Drug Availability and Time to Market: EU4 Qualitative and Quantitative Analysis of Pricing, Reimbursement, and Access Processes

    Dec 1, 2022, 00:00

  • EE608 Cost Effectiveness Analysis of a Large (Foundation Medicine) Versus a Home-Based Medium Gene Panel for Exome Sequencing: Results of the Profiler 02 Randomized Clinical Trial

    Dec 1, 2022, 00:00

  • EPH4 Burden and Characteristics of COVID-19 in France During 2020 Based on National Hospital Database

    Dec 1, 2022, 00:00

  • PCR203 A Review of the Quality-of-Life Data Use in French Economic and Public Health Assessment Committee’s (CEESP) Efficiency Opinions for Immune-Checkpoint Inhibitors (ICIS) and Chimeric Antigen Receptor T (CAR-T CELL THERAPIES)

    Dec 1, 2022, 00:00

  • HTA204 HTA Assessment of Adaptive Trials for Oncology Drugs in Europe

    Dec 1, 2022, 00:00

  • RWD161 Pharmacological Treatment Disruption in Women With Post-Partum Depression (PPD) During COVID-19: A Retrospective Cohort Study Using Claim Data

    Dec 1, 2022, 00:00

  • EPH115 Medical Cost and Prevalence of Diseases Across Different Health Insurance Systems in Japan

    Dec 1, 2022, 00:00

  • MSR119 Does Federated Analytics Preserve Statistical and Scientific Value of Real-World Data?

    Dec 1, 2022, 00:00

  • P52 Patient Preferences for Diagnostic Imaging Services Among Underserved and Rural Populations: Blueprint for Value-Based Incentives Incorporating Individual Preference Heterogeneity

    Dec 1, 2022, 00:00

  • HTA240 Indirect Comparisons of Clinical Effectiveness in NICE HTA Submissions: Software Use Trends, 2000-2022

    Dec 1, 2022, 00:00

  • CO98 Influenza Vaccine and Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study in Four Tertiary-Level Hospitals in Peru

    Dec 1, 2022, 00:00

  • EE472 Use of Health Resources and Micro-Costing Analysis of Hospitalization for Bronchiolitis and Pneumonia in Pediatric Patients: A Retrospective Study From Brazilian Perspective

    Dec 1, 2022, 00:00

  • EE659 A Novel Modelling Method for Estimating Cost Impact of a Non-Prescriptive Digital Intervention in Type 2 Diabetes

    Dec 1, 2022, 00:00

  • HSD107 Recommendations for the Design and Implementation of a Multidisciplinary Consensus Guidance for Clinical Practice on Advanced Breast Cancer in Portugal

    Dec 1, 2022, 00:00

  • HTA41 Modelling Long-Term Treatment Effects for Chronic Progressive Conditions

    Dec 1, 2022, 00:00

  • PCR93 Improving the Methods of Vignette Development for Utility Estimation: A Case Study in Pompe Disease

    Dec 1, 2022, 00:00

  • HTA29 Digital Health Interventions: A Review of Economic Evaluation Guidelines From Health Technology Assessment Agencies

    Dec 1, 2022, 00:00

  • EPH114 Impact of the COVID-19 Pandemic on HPV Vaccinations in Switzerland and Gree Road to Recovery

    Dec 1, 2022, 00:00

  • EE278 Resource Utilization and Caring Cost of People Living With Human Immunodeficiency Virus (PLHIV) in Saudi Arabia: A Tertiary Care University Hospital Experience

    Dec 1, 2022, 00:00

  • CO129 Effectiveness of a Prescription Digital Therapeutic of Cognitive-Behavioral Therapy for Insomnia in 2 Clinical Trials and in Real-World Clinical Settings: A Number Needed to Treat Analysis

    Dec 1, 2022, 00:00

  • CO32 A Systematic Review of Efficacy and Safety of Mitapivat to Treat Hemolytic Anemia in Pyruvate Kinase Deficiency

    Dec 1, 2022, 00:00

  • RWD96 The Disparity in the Utilization of Drugs for Multiple Myeloma Using Real-World Data in the US

    Dec 1, 2022, 00:00

  • PCR137 A Psycho-Onco Emotional Anxiety (POEM) Framework and Application to Understanding Emotional and Psychological Burden of Living with Cancer

    Dec 1, 2022, 00:00

  • PCR173 Patient and Carer Involvement (PI) in Real World Data Evidence Generation (RWDEG): Findings From Industry

    Dec 1, 2022, 00:00

  • EPH39 Association Between Patient-Physician Communication and Perceived Mental Health Status Among United States Adults With Cancer

    Dec 1, 2022, 00:00

  • MT42 Oxidized Zirconium Use in Primary Joint Arthroplasty: A 90-Day Episode of Care Analysis in a Large US Metropolitan Statistical Area (MSA) for Elective Total Knee Arthroplasty (TKA) and Total Hip Arthroplasty (THA)

    Dec 1, 2022, 00:00

  • EE127 Evidence and Uncertainty in an Iterative Decision-Making Framework

    Dec 1, 2022, 00:00

  • EE390 Cost-Effectiveness of the 20-Valent Pneumococcal Conjugate Vaccine vs 15-Valent Pneumococcal Conjugate Vaccine for Adults in Argentina

    Dec 1, 2022, 00:00

  • PCR73 Health-Related Quality of Life Outcomes and Associated Factors for Young Adults with Experience of Severe Malaria in Uganda: A Cross-Sectional Comparison with Community Controls

    Dec 1, 2022, 00:00

  • PCR159 Improving the Physical Function of Wheelchair Fencers

    Dec 1, 2022, 00:00

  • EPH184 A Systematic Review of the Burden of Critical Limb Ischemia (CLI) Among Patients With Peripheral Arterial Disease in Japan

    Dec 1, 2022, 00:00

  • CO173 Efficacy and Safety of Daridorexant in Patients With Insomnia: Systematic Review Meta-Analysis of Randomized Controlled Trials

    Dec 1, 2022, 00:00

  • P40 An Investigation Into the Relationship Between Choice of Model Structure and How to Adjust for Subsequent Therapies Using a Case Study in Oncology

    Dec 1, 2022, 00:00

  • RWD131 Investigating Resource Costs and the Experiences of Patients and Healthcare Professionals in the Treatment of Fabry Disease With Enzyme Replacement Therapy – A Multi-Country Study

    Dec 1, 2022, 00:00

  • EE232 Evaluate Healthcare Resource Utilization (HCRU) Among Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Active Disease

    Dec 1, 2022, 00:00

  • EPH5 Impact of the COVID-19 Pandemic on Cervical and Breast Cancer Screening

    Dec 1, 2022, 00:00

  • EE514 Treatment-Related and Non-Treatment-Related Out-of-Pocket Costs by Amyotrophic Lateral Sclerosis Disease Stage: A Cross-Sectional Patient Survey and Retrospective Chart Review

    Dec 1, 2022, 00:00

  • RWD134 Real-World Effectiveness of Atezolizumab Plus Bevacizumab in the Patients With Hepatocellular Carcinoma: A Multi-Institutional Cohort in Taiwan

    Dec 1, 2022, 00:00

  • EE515 Cost Per Responder Analysis of Methotrexate Versus Other Therapies in the Treatment of Moderate to Severe Plaque Psoriasis in Italy

    Dec 1, 2022, 00:00

  • HTA177 Current Developments in the Market Access Conditions for Gene Therapies in Germany

    Dec 1, 2022, 00:00

  • EPH141 Dispensing Patterns for Rabies in Humans: A South African Database Analysis

    Dec 1, 2022, 00:00

  • SA54 Physical and Mental Health Among Frontline Healthcare Workers During COVID-19 Pandemic in Hungary

    Dec 1, 2022, 00:00

  • HPR174 Social Value Evaluation of Long-Term Care Insurance in Korea: Social Return on Investment Approach (SROI)

    Dec 1, 2022, 00:00

  • EPH102 Public Health Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in Chile

    Dec 1, 2022, 00:00

  • HPR12 Treatment Inequities Among Cancer Patients Due to Reimbursement: From the Perspective of 130 Medical Oncologists

    Dec 1, 2022, 00:00

  • MSR22 Strategies for Effective Patient Advocacy Group Engagement in the Development and Fielding of Online Patient Burden Surveys

    Dec 1, 2022, 00:00

  • EE561 Estimation of the Economic Burden of Renal Complications of Diabetes in Algeria

    Dec 1, 2022, 00:00

  • HSD91 Introducing Time-Driven Activity-Based Costing in Chile: Medium Costs Estimation of Breast Cancer Biopsies in a Public Anatomic Pathology Laboratory

    Dec 1, 2022, 00:00

  • PCR77 Factors to Consider in Deciding on B/Ts Dmards to Manage Inflammatory Arthritis From a Patient Perspective: A Systematic Review

    Dec 1, 2022, 00:00

  • EE590 Duration and Costs of Hypoparathyroidism After Total Thyroidectomy for Thyroid Cancer: A French Nationwide Claims Database Study (1-YEAR FOLLOW-UP)

    Dec 1, 2022, 00:00

  • SA24 Effects of Navigated rTMS for the Hemiparetic Upper Extremity Motor Function in Stroke Patients – Pilot Study

    Dec 1, 2022, 00:00

  • HPR167 A Comparison of ICER Health-Benefit Price Benchmarks in the United States to Drug Prices in the United Kingdom and France

    Dec 1, 2022, 00:00

  • HTA231 Estimation of Expected Years of Living With Disability in Patients With Non-Small Cell Lung Cancer

    Dec 1, 2022, 00:00

  • EE470 Zanubrutinib Versus Ibrutinib to Treat Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A Cost Per Responder Model From a Payer Perspective in the United States

    Dec 1, 2022, 00:00

  • PCR179 Estimating Health Utilities in Patients with Epilepsy Using the SF-6D

    Dec 1, 2022, 00:00

  • HTA19 How Are United States ICER’S Evidence Ratings Determined? A Systematic Review of ICER’S Evidence Ratings in Evidence Reports for New Drugs in 2020 and 2021

    Dec 1, 2022, 00:00

  • HTA217 Reimbursement of Drugs for Rare Diseases in Canada: Do Treatment Cost and Cost-Effectiveness Ratio Correlate With Epidemiologic Factors?

    Dec 1, 2022, 00:00

  • EE563 Evaluating the Cost-Utility of Intravesical Bacillus Calmette-Guérin Versus Radical Cystectomy in Patients With High-Risk Non-Muscle-Invasive Bladder Cancer in the UK

    Dec 1, 2022, 00:00

  • RWD9 Real-World Relative Dose Intensity in Patients With Advanced or Metastatic Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors in Sweden

    Dec 1, 2022, 00:00

  • EPH42 Long-Term Impacts of Air Pollution on Health-Related Quality of Life Among Older Adults in China

    Dec 1, 2022, 00:00

  • HPR47 Comparison of the Characteristics and Costs of Vulnerable Populations Hospital Stays in France Regarding Their Coverage Type Between 2011 and 2021

    Dec 1, 2022, 00:00

  • EE100 An Approach to Value-Based Pricing for Digital Health Applications in Germany

    Dec 1, 2022, 00:00

  • EE344 A Systematic Review: Model-Based Cost-Effectiveness Analyses (CEAs) of Guideline-Directed Disease-Modifying Medical Therapies (GDMT) for Heart Failure with Reduced Ejection Fraction (HFrEF)

    Dec 1, 2022, 00:00

  • HPR190 Evaluating the Impact of the Entry of IVD-R in the Biopharmaceutical Industry, With a Focus on Evidence Requirements and Time to Launch

    Dec 1, 2022, 00:00

  • EPH118 Healthcare Systems Sustainability and Resilien Creating an Index

    Dec 1, 2022, 00:00

  • HTA167 Transition to New Danish HTA Process

    Dec 1, 2022, 00:00

  • EPH40 Polyconsultant Patient: A Dynamic Definition for Users Attending Primary Care Emergency Services

    Dec 1, 2022, 00:00

  • EE271 Health State Utility Values Used in Economic Evaluation of Meningococcal Vaccination: A Systematic Review

    Dec 1, 2022, 00:00

  • PCR20 Diversity of Patient Support Programs for Severe Asthma Treated with Biologic Therapies – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE90 Are There Specificities for Assessing Quality of Life and Utilities in Rare Diseases for Economic Evaluation in Fran A Case Study of Published CEESP Opinions

    Dec 1, 2022, 00:00

  • P28 Evidence-Informed Deliberative Process for Health Technology Assessment in Spain

    Dec 1, 2022, 00:00

  • MSR9 A Systematic Literature Review of the Economic and Humanistic Burden of Duchenne Muscular Dystrophy

    Dec 1, 2022, 00:00

  • HSD32 Early Access in Fran Reasons for Refusals and Impact on Market Access

    Dec 1, 2022, 00:00

  • HTA198 The Influence of the Claimed Benefit Versus the Given Benefit on the Negotiated Rebate During the German Health Technology Assessment

    Dec 1, 2022, 00:00

  • HTA223 The Current Status and Challenges of Value Assessment in Prevention and Treatment for Alzheimer’s Disease Dementia in Japan

    Dec 1, 2022, 00:00

  • EE300 Health Care Resource Utilisation (HCRU) and Corresponding Costs of Respiratory Syncytial Virus (RSV) Admissions Before the Age of Two in England

    Dec 1, 2022, 00:00

  • RWD121 Assessing the Use of Variational Bayes for Large Real-World Data

    Dec 1, 2022, 00:00

  • SA45 Practical Considerations for Developing PICO Statements for Humanistic Burden Reviews: How to Get It Right

    Dec 1, 2022, 00:00

  • HTA83 Role of Quality of Life in Health Technology Assessment Agency Final Recommendations: Insights and Lessons From Review of NICE Technology Assessment Reports (2019-2022)

    Dec 1, 2022, 00:00

  • HTA117 A Targeted Literature Review Into Incorporating Environmental Impact of Healthcare Into Health Technology Assessments (HTAS)

    Dec 1, 2022, 00:00

  • EPH18 Neovascular Age-Related Macular Degeneration: Prevalence and Treatment With Anti-VEGF From the Perspective of the Italian National Health System

    Dec 1, 2022, 00:00

  • PCR1 Comparison of Infant’s CRY/Fuss Report Between Parental Perception and Recording Analysis, and Its Potential Implications on Parental Mental Health

    Dec 1, 2022, 00:00

  • EE132 Budget Impact Related to Complications on Pre-Bariatric Surgery Patients in Brazilian Public Healthcare System

    Dec 1, 2022, 00:00

  • EE498 Cost of Follow-Up After an Ischemic Cerebrovascular Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results from the Reality Study

    Dec 1, 2022, 00:00

  • HPR91 Disease-Specific Hardship Financing in India: A Pooled Cross-Section Analysis of Inpatient and Outpatient Cases

    Dec 1, 2022, 00:00

  • CO3 Sensitivity to Change of the Oxford Participation and Activities Questionnaire in People With Parkinson’s

    Dec 1, 2022, 00:00

  • PCR289 Building a Practical Strategy and Framework for Diverse and Inclusive Involvement of Patients and Carers in Real World Data Evidence Generation (RWDEG)

    Dec 1, 2022, 00:00

  • MSR12 Validation of Four EQ-5D-5L Crosswalk Prediction Models From Promis-29 in Patients With Cardiovascular Disease

    Dec 1, 2022, 00:00

  • EE526 Public Health Impact and Cost-Effectiveness of Recombinant Zoster Vaccine for Vaccinating Immunocompromised Adults Against Herpes Zoster in the United States

    Dec 1, 2022, 00:00

  • PCR229 Two Simple Methods for Daily Measuring Compliance With Oral Nutritional Supplements in the Community: Electronic Self-Report Method Versus Image-Based Method

    Dec 1, 2022, 00:00

  • EPH179 The Economic Impact of Diabetic Ketoacidosis (DKA) in People with T1DM at High Risk for DKA: A Structured Literature Review

    Dec 1, 2022, 00:00

  • EE224 Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring (RTCGM) vs Self-Monitoring of Blood Glucose (SMBG) in Patients With Type 1 Diabetes in the Netherlands

    Dec 1, 2022, 00:00

  • HTA213 Seven Years of HTA in Singapore: Practices and Key Drivers

    Dec 1, 2022, 00:00

  • EE392 Cost-Effectiveness Analysis of Atrial Fibrillation Screening for a 50–65-Year-Old Population With Elevated Stroke Risk

    Dec 1, 2022, 00:00

  • HPR142 The Impact of Cost-Shifting Policies on the Pharmaceutical Sector in Greece During the Financial Crisis

    Dec 1, 2022, 00:00

  • EPH28 Underage Drinking in Adolescents

    Dec 1, 2022, 00:00

  • EPH78 In the Crosshairs: Eating and Fluid Consumption Habits of the Students of the International Bachelor Program at the University of Pécs

    Dec 1, 2022, 00:00

  • EE259 US Reference Pricing Impact on Transparency, Pricing, and Access in the EU4 Final

    Dec 1, 2022, 00:00

  • PCR114 Patient-Voice RWE: Comparative Burden Collected From an Online Social Platform

    Dec 1, 2022, 00:00

  • HTA169 Health Technology Assessment and Reimbursement for Select Oncology Therapies in European Major Markets

    Dec 1, 2022, 00:00

  • EE281 Freestyle Libre 2 Flash Glucose Monitoring System: Budget Impact and Cost-Utility Analyses in Type 1 Diabetes From the Italian NHS Perspective

    Dec 1, 2022, 00:00

  • HTA69 Delay of Innovative Oncology Treatments - Case From Bulgaria

    Dec 1, 2022, 00:00

  • EPH153 Increased Prevalence of Post-Traumatic Stress Syndrome Among Healthcare Workers During the Coronavirus Epidemic

    Dec 1, 2022, 00:00

  • HTA234 Impact of Cost-Effectiveness Assessment Scheme (as a Part of HTA System) on Drug Prices in Japan

    Dec 1, 2022, 00:00

  • EPH204 What Doesn't Kill You: Re-Evaluating Our Approach to High Burden, Low Mortality Chronic Diseases With a Focus on Migraine and Multiple Sclerosis

    Dec 1, 2022, 00:00

  • PCR49 Patient Reported Outcomes in Randomized Controlled Trials of Nervous System and Mental Health Disorders: Current Status in India

    Dec 1, 2022, 00:00

  • EE165 Cost-Effectiveness Analysis of Liposomal Formulation of Daunorubicin and Cytarabine (CPX-351) for the Treatment of Adult Patients With Newly Diagnosed Therapy-Related AML or AML With Myelodysplasia-Related Changes in Greece

    Dec 1, 2022, 00:00

  • HPR110 ESG in Pharma Procurement, Not More Than Wishful Thinking? A Quantitative View on Award Criteria in Tenders in the EU5 From 2011 to 2020

    Dec 1, 2022, 00:00

  • EE501 Making R-Based Economic Models Even Shinier With Web-Based Interfaces

    Dec 1, 2022, 00:00

  • RWD1 Factors Affecting Korean Medicine Health Care Use of Functional Dyspepsia in Korea: Analysis of Korea Health Panel Survey 2017

    Dec 1, 2022, 00:00

  • PCR85 Modifying QALY

    Dec 1, 2022, 00:00

  • EPH106 Evaluating Changes in the Diagnostic Setting and Treatment of Bacterial Sexually Transmitted Infections in Germany During COVID-19: A Descriptive Analysis of German Claims Data From 2018-2021

    Dec 1, 2022, 00:00

  • EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia

    Dec 1, 2022, 00:00

  • HTA162 Assessing Literature Reviews in NICE Single and Multiple Technology Appraisals

    Dec 1, 2022, 00:00

  • EE270 Economic Burden of Young Onset Parkinson's Disease: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE657 Age and Gender Differences in Direct Non-Health Costs for Formal and Informal Assistance, Costs for Productivity Loss Among Italian Behçet Patients

    Dec 1, 2022, 00:00

  • EE163 Analysis of Healthcare Resource Use of the Robotic Surgery System for Rectal Cancer in Japan

    Dec 1, 2022, 00:00

  • RWD147 Demonstrating the Application of Real-World Evidence for Health Technology Assessment Using a Federated Data Network

    Dec 1, 2022, 00:00

  • RWD84 The Role of Real-World Evidence in Cell and Gene Therapy Regulatory and Health Technology Assessment Decisions

    Dec 1, 2022, 00:00

  • CO94 Tepotinib Compared With Chemoimmunotherapy in First-Line Non-Small Cell Lung Cancer (NSCLC): Matching Adjusted Indirect Comparison (MAIC) of VISION in MET Exon 14 (METex14) Skipping NSCLC and KEYNOTE-189 in Wild-type NSCLC

    Dec 1, 2022, 00:00

  • HTA39 Estimating the True Cost of Weight-Based Chemotherapy

    Dec 1, 2022, 00:00

  • SA80 Data Extraction Templates in Systematic Literature Reviews: How Systematic Are We?

    Dec 1, 2022, 00:00

  • HTA35 Should Health Technology Assessment (HTA) Bodies Utilize Living HTA Tools? Validation of LiveSLR® and LiveNMA™ Tools Using ICER’S Class Review in Relapsed Refractory Multiple Myeloma (RRMM)

    Dec 1, 2022, 00:00

  • MSR91 Automated Tools to Support Screening in Literature Reviews: What's Out There for Reviewers?

    Dec 1, 2022, 00:00

  • EE111 Cost-Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Chronic Heart Failure Irrespective of Left-Ventricle Ejection Fraction in the Netherlands

    Dec 1, 2022, 00:00

  • CO82 The Assessment of Surrogate Endpoints and Their Impact on HTA Recommendations

    Dec 1, 2022, 00:00

  • EE624 Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the Vaccination Programme in the UK

    Dec 1, 2022, 00:00

  • CO177 Association Between the Sarcomatoid Status and Percentage of Sarcomatoid on the Clinical Outcomes of Localized Renal Cell Carcinoma Post Nephrectomy

    Dec 1, 2022, 00:00

  • HPR54 Patient Impact of Transferring Hospital-Only Medicines Dispensing to Community Pharmacies: A Longitudinal Prospective Study

    Dec 1, 2022, 00:00

  • HPR20 Comparative Analysis of Expenditure on Pharmaceuticals in Czechia and Slovakia – How to Understand the OECD Statistics

    Dec 1, 2022, 00:00

  • HPR156 Payment and Reimbursement Models for Innovative High-Priced Hospital Drugs in the Netherlands: A Survey of Stakeholder's Attitudes and Experiences

    Dec 1, 2022, 00:00

  • EE665 Cost-Minimisation Analysis of Oral Semaglutide Versus Dulaglutide in Patients With Type 2 Diabetes Requiring Treatment With a GLP-1 Receptor Agonist

    Dec 1, 2022, 00:00

  • EE59 Assessing Economic Cost of Treatment of an Episode of Malaria and Its Effect on the Well-Being of Households in Comé District Health (CDH), South-West Benin

    Dec 1, 2022, 00:00

  • MSR45 Challenges in Extrapolation When There Are Multiple Health Outcomes

    Dec 1, 2022, 00:00

  • EE223 Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients With Advanced Follicular Lymphoma: A Cost Analysis

    Dec 1, 2022, 00:00

  • PCR72 Effects on Employment for Adults Within the Early Stages of Manifest Huntington's Disease: A Cross-Sectional Analysis Using Enroll-HD

    Dec 1, 2022, 00:00

  • EE450 The Burden of Intraoperative Hypotension in Patients Undergoing High-Risk Noncardiac Surgery and the Role of a Machine Learning-Derived Algorithm to Optimize Its Management: What Are We Missing Ignoring Supportive Innovations?

    Dec 1, 2022, 00:00

  • HTA191 Health Technology Assessment in Gree Evaluation of Current Status and Prospects

    Dec 1, 2022, 00:00

  • PCR76 Do We Really Need a Study Looking at That? A Best-Worst Scaling Study Assessing Methodological Research Priorities According to the Patient Preference Research Community

    Dec 1, 2022, 00:00

  • HPR95 Opportunities and Challenges for Value Added Medicines: Results of a Scoping Research Based on Expert Interviews

    Dec 1, 2022, 00:00

  • MSR52 Target Trial Emulation (TTE) for Real World Data Analyses to Support HTA Decisions

    Dec 1, 2022, 00:00

  • HPR177 Digital Affinity Survey of Payers in the Healthcare Industry in Turkiye

    Dec 1, 2022, 00:00

  • MSR43 The Use of Safety-Engineered Devices in Preventing Needle-Stick Injuries: A Budget Impact Analysis

    Dec 1, 2022, 00:00

  • Key Trends in HTA Policy: Present and Future

    Dec 1, 2022, 00:00

  • EPH122 Healthcare Consumptions in Patient with Early Ageing Disease: Case-Control Study From a National Claims Database

    Dec 1, 2022, 00:00

  • EPH117 Coinfections in COVID-19 Patients in India: A Systematic Review

    Dec 1, 2022, 00:00

  • EE575 Cost-Effectiveness of Low-Dose Computed Tomography Screening for Lung Cancer

    Dec 1, 2022, 00:00

  • EE254 A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in Patients With Inflammatory Bowel Disease in Italy

    Dec 1, 2022, 00:00

  • EE108 Economic Evaluation of the IGRA Screening Test for the Detection of Micobacterium Tuberculosis Infection: An Analysis for the Italian Health System

    Dec 1, 2022, 00:00

  • EPH167 Proportions of Avoidable GP Visits in Fran Findings From a National Claims Database

    Dec 1, 2022, 00:00

  • SA13 The Impact of the COVID-19 Pandemic on Collaboration and Innovation in Antiviral Drug Development: A Multi-Stakeholder Systems Dynamics Analysis

    Dec 1, 2022, 00:00

  • RWD70 Electronic Implementation of Patient-Reported Outcomes: Challenges and Potential Solutions

    Dec 1, 2022, 00:00

  • EPH209 Metformin 15-Year Consumption Analysis in Selected European Countries

    Dec 1, 2022, 00:00

  • EE246 Real-World Costs and Health Care Resource Utilization (HCRU) Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US

    Dec 1, 2022, 00:00

  • RWD29 Use of Telemedicine Services and Health Outcomes in Hypertensive Patients in Pre- and Post-COVID-19 Periods in the United States

    Dec 1, 2022, 00:00

  • PCR184 Urban/Rural Differences in Preferences for EQ-5D-5L Health States: A Study of a Multi-Ethnic Region in China

    Dec 1, 2022, 00:00

  • MT14 How Should Clinical Outcomes Factor Into Purchasing Decisions About Macintosh-Style Laryngoscopes?

    Dec 1, 2022, 00:00

  • HTA249 Method in the Madness – Acceptance of Indirect Evidence in Joint Clinical Assessments

    Dec 1, 2022, 00:00

  • PCR136 Patient and Health Care Professional Experiences of Suboptimal Insulin Dosing

    Dec 1, 2022, 00:00

  • HTA73 Evaluation of NICE Severity Modifiers

    Dec 1, 2022, 00:00

  • HPR83 Unequal Access of Innovative Dermatology Products Across Canada

    Dec 1, 2022, 00:00

  • EE146 Cost-Effectiveness of Axicabtagene Ciloleucel Versus Other CAR T-Cell Therapies in the Treatment of Diffuse Large B-Cell Lymphoma in France

    Dec 1, 2022, 00:00

  • EE142 The Clinical Benefits and Costs of Potential Cervical Cancer Screening Strategies in the Czech Republic

    Dec 1, 2022, 00:00

  • CO162 Association Between Hypotension and Drug Interaction of Direct-Acting Antiviral Agents in Hepatitis C Virus-Infected Patients: A Multicenter Study in Taiwan

    Dec 1, 2022, 00:00

  • HSD23 Operational Waste Savings on Health in a Value-Based Patient Drug Safety Program

    Dec 1, 2022, 00:00

  • EE307 Costs of Treating Soft Tissue Sarcomas and Infantile Fibrosarcoma in Pediatric Patients in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • HPR44 Innovation Value Framework - Evidence From EU-4 and UK

    Dec 1, 2022, 00:00

  • PCR122 Health-Related Quality of Life of Patients With Gall Bladder Cancer: A Targeted Review

    Dec 1, 2022, 00:00

  • EE631 Cost Minimization Analysis of the Switch to a New Immunization Schedule With a Hexavalent (DTAP-HBV-HIB-IPV) Vaccine in Algeria

    Dec 1, 2022, 00:00

  • HSD82 Real-World Assessment of Antiplatelet Treatment Therapies for Patients With Acute Coronary Syndrome (ACS) in the United Kingdom

    Dec 1, 2022, 00:00

  • EE562 Cost-Effectiveness and Budget Impact Analyses of Implementing the First Pillar of Patient Blood Management, With Intravenous (IV) Ferric Carboxymaltose (FCM), on the Turkish Healthcare System

    Dec 1, 2022, 00:00

  • PCR14 A Literature Review of Methodology Used in In-Trial Interview Studies in Clinical Development

    Dec 1, 2022, 00:00

  • PCR99 Exploring Relative Weighting and Ranking of Potential Bolt-on Item for the Eq-5D-5L-Hk by Pairwise Comparison in Hong Kong Context

    Dec 1, 2022, 00:00

  • CO43 The Role of Different Biomarkers in the Prognosis of COVID-19 Infection

    Dec 1, 2022, 00:00

  • PCR63 Using Patient Preference to Inform Ritlecitinib Dose Selection for Alopecia Areata Treatment

    Dec 1, 2022, 00:00

  • RWD132 Suitability of Nordic Real-World Data to Support EU Regulatory Decision Making

    Dec 1, 2022, 00:00

  • HTA243 Health Technology Assessment and Reimbursement of Medical Devices in England, France, and Germany

    Dec 1, 2022, 00:00

  • EE83 Cost-Effectiveness Analysis of an Active Transcutaneous Bone Conduction Implant for Patients With Conductive or Mixed Hearing Loss or Single-Sided Deafness in Turkey

    Dec 1, 2022, 00:00

  • PCR231 Associations of Preoperative Anxiety/Depression (EQ-5D-5L) With Pre- and Postoperative Health-Related Quality of Life for Hip and Knee Replacement

    Dec 1, 2022, 00:00

  • MSR56 Measuring HIV Health Management Efficiency Among Health Insurers in Colombia Using Data Envelopment Analysis

    Dec 1, 2022, 00:00

  • HPR103 Pricing Negotiations of ASMR IV Drugs in Fran Impact of the Latest LEEM-CEPS Framework Agreement

    Dec 1, 2022, 00:00

  • EE167 The Socioeconomic Impact of Disability Progression in Multiple Sclerosis: A Retrospective Cohort Study of the German Neurotransdata (NTD) Registry

    Dec 1, 2022, 00:00

  • HTA7 Implementation of Comprehensive Criteria for Decision Making Process of Pricing and Reimbursement in Algeria

    Dec 1, 2022, 00:00

  • PCR226 Patient and Public Involvement in Research: Reflections on Open Health Collaborations

    Dec 1, 2022, 00:00

  • EE166 Cost-Effectiveness of the Pneumococcal Conjugate Vaccine 10 Versus 13 on Pneumococcal Disease in Children in Sweden

    Dec 1, 2022, 00:00

  • EE558 Cost-Effectiveness of Direct Transfer of Acute Ischemic Stroke Patients to Angiography Suite

    Dec 1, 2022, 00:00

  • EE656 A Cost-Utility Analysis of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, a Rare Disease, in Spain

    Dec 1, 2022, 00:00

  • RWD26 Real World Evidence Studies Presented in ISPOR 2022: A Descriptive Analysis of Research Posters

    Dec 1, 2022, 00:00

  • MT13 A Dynamic Budget Impact Analysis of Surgical Treatment for Obesity in Greece

    Dec 1, 2022, 00:00

  • P27 Rationing in an Era of Multiple Tight Constraints: Is Cost-Utility Analysis Still Fit for Purpose?

    Dec 1, 2022, 00:00

  • MSR88 Can the Promis®-29 Profile be Used to Predict SF-36 Physical and Mental Health Summary Scores?

    Dec 1, 2022, 00:00

  • HPR24 Critical Analysis on Time-to-Reimbursement of Rare Disease Drugs: The Italian Case (AIFA Commissions 2018-2022)

    Dec 1, 2022, 00:00

  • HTA192 Precision Versus Non-Precision Oncology Drug Submissions to the National Centre for Pharmacoeconomics in Ireland

    Dec 1, 2022, 00:00

  • HPR64 Opportunities and Challenges for Innovative Drugs in China

    Dec 1, 2022, 00:00

  • EE28 Cost-Effectiveness of Glucose-Lowering Therapies as Add-on to Standard Care for People With Type 2 Diabetes in Malaysia

    Dec 1, 2022, 00:00

  • HSD58 Country Differences in the Clinical Manifestations and Treatment Patterns of Patients With Eosinophilic Granulomatosis With Polyangiitis (EGPA): A European Perspective

    Dec 1, 2022, 00:00

  • EE600 Cumulative Cardiovascular or Renal Disease (CVRD) Hospital Costs for Type 2 Diabetics Free of CVRD at Baseline: A 5-Year Cohort Study in the SNDS Nationwide Claims Database

    Dec 1, 2022, 00:00

  • CO53 Real-World Clinical Outcomes and Efficiency of a New Steerable Sheath Technology for Radio-Frequency Ablation in Chinese Patients with Atrial Fibrillation

    Dec 1, 2022, 00:00

  • EE448 Assessing the Cost-Effectiveness of Reducing Acute Exacerbations in Patients With COPD

    Dec 1, 2022, 00:00

  • P67 Cumulative Effect of Depression on Health Worsening During The COVID-19 Lockdown Among Diabetic Patients in Europe

    Dec 1, 2022, 00:00

  • PCR228 Developing Treatment Attributes for a Patient Preference Survey in Inflammatory Bowel Disease

    Dec 1, 2022, 00:00

  • RWD136 User Profile, Strip Use Habits, and Benefits of the Freestyle Libre System: A Repeated Cross-Sectional Survey of Community Pharmacies in Portugal

    Dec 1, 2022, 00:00

  • RWD86 Healthcare Resource Utilization (HCRU) of United States ROS1+ Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Tyrosine Kinase Inhibitors (TKIs): Analysis of Electronic Medical Transcription Records

    Dec 1, 2022, 00:00

  • EE506 Budget Impact Analysis of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico

    Dec 1, 2022, 00:00

  • EPH63 Exploring the Potential Public Health Benefits of a Respiratory Syncytial Virus (RSV) Vaccine Candidate (Ad26.RSV.preF/RSV) Among Individuals Aged 65 Years and Older in the UK: A Preliminary Mathematical Modelling Approach

    Dec 1, 2022, 00:00

  • HTA255 Recommendations on the Use of Artificial Intelligence and Machine Learning in Systematic Literature Reviews Submitted as Part of the Evidence Package in Health Technology Assessment

    Dec 1, 2022, 00:00

  • PCR95 Functional Quality of Life Among People Living With Obesity: A Longitudinal Cohort of Patient Reported Outcomes

    Dec 1, 2022, 00:00

  • CO132 Focuses on the Prevalence and Impact of Metabolic Syndrome on the Outcome of Patients With Acute Coronary Syndrome in Iraq and Hungary

    Dec 1, 2022, 00:00

  • HPR184 Uncertainties Around Tumour Agnostic Therapies in Europe: Barriers and Facilitators of Patient Access

    Dec 1, 2022, 00:00

  • HSD40 Development of the Patient-Focused Heart Failure Screening Questionnaire to Support a Predictive Heart Failure Algorithm in Patients Implanted With a Cardiac Electronic Device

    Dec 1, 2022, 00:00

  • PCR287 The Social Burden of the Caregivers of Alzheimer's Disease Patients in Egypt

    Dec 1, 2022, 00:00

  • RWD63 Comparison of Certified Secure Processing Environments (SPE) – Novel Platforms for Collection, Augmentation, Structuring, Transfer, Management, Analysis, Sharing, Reporting, and Storage of Sensitive Data?

    Dec 1, 2022, 00:00

  • MSR59 Replication and Extrapolation From RCTs to Observational Data to Predict Treatment Effects: Why, What, How

    Dec 1, 2022, 00:00

  • HPR39 Access to Orphan Drugs in Hungary

    Dec 1, 2022, 00:00

  • EE187 Healthcare Resource Utilization in Non-Cystic Fibrosis Bronchiectasis (NCFB) Patients With Commercial Insurance Coverage in the US

    Dec 1, 2022, 00:00

  • EE320 Humanistic and Economic Burden of Advanced Hepatocellular Carcinoma: A Systematic Review

    Dec 1, 2022, 00:00

  • MSR23 Health Economic Evaluations Alongside New Clinical Trial Designs – Results of an International Expert Panel Workshop

    Dec 1, 2022, 00:00

  • CO104 Real-World Impact of a Prescription Digital Therapeutic on Retention in Treatment and Relapse Indicators in Patients With Opioid Use Disorder

    Dec 1, 2022, 00:00

  • EE235 Cost Analysis of Enzyme Replacement Therapy Domicile Infusion in the Fabry and Gaucher Syndromes

    Dec 1, 2022, 00:00

  • EE148 Canadian Cost-Effectiveness Analysis of Deferiprone Compared to Deferoxamine and Deferasirox for the Treatment of Iron Overload in Patients With Sickle Cell Disease and Other Anemias

    Dec 1, 2022, 00:00

  • EPH198 Assessing the Validity of Netherlands Linked Routine Healthcare Resource Utilisation Data in the Investigation of Single-Inhaler Triple Therapy Effectiveness (INTREPID Trial)

    Dec 1, 2022, 00:00

  • EE214 Modelling Cost Determinants for Treating Metastatic Castration-Resistant Prostate Cancer: An Italian National Healthcare System's Perspective Cost Analysis

    Dec 1, 2022, 00:00

  • RWD127 Disparity in Health Care Cost and Resource Utilization in Children With Autism: A Demographic Evaluation

    Dec 1, 2022, 00:00

  • HTA185 HTA Indexing in the Purpose-Built INAHTA and CRD HTA Databases

    Dec 1, 2022, 00:00

  • PCR291 Preferences for Key Features of Gonadotropin-Releasing Hormone Analogues Among Women With Endometriosis in the United States

    Dec 1, 2022, 00:00

  • EE22 Average CET Limit: Is It Possible to Introduce a Single CET for the Whole EEA?

    Dec 1, 2022, 00:00

  • EE3 Cost-Utility Analysis of Xelox Plus Bevacizumab Versus Xelox for Metastatic Colorectal Cancer Treatment in Thailand

    Dec 1, 2022, 00:00

  • PCR48 Meaningful Change Is a Perception, Not Only a Number: A Review of Qualitative Interviews Exploring Meaningful Changes in Symptoms

    Dec 1, 2022, 00:00

  • EE268 Per-Member Per-Month (PMPM) Expenditure Value in Oncology: Updating a Focused Literature Review

    Dec 1, 2022, 00:00

  • EE491 Real-World Costs, Health Care Resource Utilization (HCRU), and Outcomes Among Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) in the US

    Dec 1, 2022, 00:00

  • RWD66 Application of the Target Trial Framework for Estimating Comparative Effectiveness Using Real-World Data - A Systematic Review

    Dec 1, 2022, 00:00

  • EE636 Cost of Follow-Up After a Peripheral Arterial Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study

    Dec 1, 2022, 00:00

  • Award Winners

    Dec 1, 2022, 00:00

  • HPR62 Equity and Outcome Events in Patients With Hidradenitis Suppurativa: Exploring Effect Modifiers Associated With HS Diagnostic Delay

    Dec 1, 2022, 00:00

  • HTA262 Cost Effectiveness Analysis of Paclitaxel Micellar for Treatment of First Relapse Platinum Sensitive Ovarian Cancer

    Dec 1, 2022, 00:00

  • EE553 Hospitalisation and Healthcare Costs in Adults with Systemic Lupus Erythematosus in Sweden: A Real-World Observational Cohort Study

    Dec 1, 2022, 00:00

  • EE534 Economic Evaluations of HIV-1 Disease in South Africa – A Targeted Literature Review

    Dec 1, 2022, 00:00

  • HTA239 The Challenge of Confidential Commercial Arrangements in Health Technology Assessment: How Often Do They Feature in NICE Technology Appraisal Evaluations?

    Dec 1, 2022, 00:00

  • HSD34 The Development and Validation of a Novel Discrete Simulation Tool for Modeling the Operational Efficiency of Inpatient Electrophysiology Services

    Dec 1, 2022, 00:00

  • HTA141 Does NICE’s New Severity Modifier Capture the Value of Treatments for Long-Term Progressive Diseases? A Retrospective Analysis of Past Appraisals in Multiple Sclerosis

    Dec 1, 2022, 00:00

  • RWD98 Variation in COVID-19 Length of Stay Due to Social Factors in the US – Estimation Using Integration of CDC/ATSDR's Social Vulnerability Index (SVI) and Healthcare Claims Data

    Dec 1, 2022, 00:00

  • PCR189 Health-Related Quality of Life in Patients Receiving Oral Anti-Coagulants: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • CO21 Validation of Crossover Adjustment Outcomes in a Randomized Clinical Trial (RCT) Using Real-World Evidence (RWE) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • HSD26 Real-World Patterns of Care and Outcomes Among Advanced Cervical Cancer Patients in England: Retrospective Analysis of the NCRAS Datasets, 2012-2019

    Dec 1, 2022, 00:00

  • EE330 Productivity Losses Associated with Spinal Muscular Atrophy (SMA) in Adult Patients in Sweden Not Treated With Disease Modifying Therapies: A Population-Based Study

    Dec 1, 2022, 00:00

  • HSD86 Contribution of Clinical Pharmacy Services to the Achievement of Diabetes and Hypertension-Related Quality Measures Among Medicare Patients

    Dec 1, 2022, 00:00

  • EE262 An Economic Evaluation and Return on Investment of the Community Benefit of the Australian Pregnancy Register of Anti-Seizure Medications

    Dec 1, 2022, 00:00

  • EE356 Budget Impact of Extracorporeal Photopheresis for Treatment of Chronic Lung Allograft Dysfunction Following Lung Transplantation in Switzerland – Results of a Single-Center Retrospective Chart Review

    Dec 1, 2022, 00:00

  • PCR24 The Humanistic and Economic Impact of Fibrodysplasia Ossificans Progressiva on Primary Caregivers: Results From an International Burden of Illness Survey

    Dec 1, 2022, 00:00

  • SA41 Kinesiophobia After Returning to Play in Football

    Dec 1, 2022, 00:00

  • EE360 Health Care Resource Utilization With Asciminib and Bosutinib Among Adults With Chronic Myeloid Leukemia in Chronic Phase Previously Treated With ≥2 Tyrosine Kinase Inhibitors: Week 48 and Week 96 Results From ASCEMBL Trial

    Dec 1, 2022, 00:00

  • EE50 A Cost-Consequence Model of Using the 21-Gene Breast Recurrence Score Assay to Identify Patients With Early-Stage Node-Positive Breast Cancer Who Benefit From Adjuvant Chemotherapy in the Netherlands

    Dec 1, 2022, 00:00

  • HTA98 Distribution of the Positive Added Medical Benefit According to the Early Access Status and the Potential Public Health Interest– Analysis of the French HTA Body Opinions (HAS Transparency Committee)

    Dec 1, 2022, 00:00

  • Projecting the Economic Impact of Compensating Living Kidney Donors in the United States: Cost-Benefit Analysis Demonstrates Substantial Patient and Societal Gains

    Dec 1, 2022, 00:00

  • EE255 Budget Impact Analysis of the Introduction of a Prognostic Prostate Genomic Biomarker Cancer Test in the Management of Localized Prostate Cancer Patients for Greece

    Dec 1, 2022, 00:00

  • HTA105 Scope, Feasibility and Challenges of Valuing Disability in Cost-Effectiveness Analyses Submitted to the French National Authority for Health (HAS)

    Dec 1, 2022, 00:00

  • CO86 Clinical Outcomes of Diabetic Macular Edema Patients Treated With Faricimab and Aflibercept: A Subcohort Analysis of 20/50 or Worse Visual Acuity Across Faricimab Phase 3 Clinical Trials

    Dec 1, 2022, 00:00

  • HSD35 Healthcare Resource Utilization (HCRU) in Treatment of Patients With Localized/Locally Advanced Prostate Cancer (LPC/LAPC) in a Portuguese Comprehensive Cancer Center (PCCC)

    Dec 1, 2022, 00:00

  • EE113 Discrete Event Simulation in Obesity: A Feasibility Study

    Dec 1, 2022, 00:00

  • MSR50 Comparing Survival Extrapolation Outcomes Using Different Network Meta-Analyses (NMA) Methods: An Application in Patients With Metastatic Renal Cell Carcinoma (MRCC) Treated With Immunotherapy (IO) Based Combinations

    Dec 1, 2022, 00:00

  • EE55 Comparative Cost-Utility Analysis of Budesonide and the Six Food Elimination Diet (SFED) for the Prophylaxis of Patients With Eosinophilic Esophagitis (EoE) in the Austrian Setting

    Dec 1, 2022, 00:00

  • HSD66 The Association Between Patients’ Socio-Demographic Characteristics and Biologic Treatment Initiation: Real-World Evidence From a 14-Year Cohort of Ulcerative Colitis Patients in Israel

    Dec 1, 2022, 00:00

  • EE594 The Cost of Care Among Infantile and Child Spinal Muscular Atrophy Patients: RWE from a Large Claims Database

    Dec 1, 2022, 00:00

  • Analyzing the Pain/Discomfort and Anxiety/Depression Composite Domains and the Meaning of Discomfort in the EQ-5D: A Mixed-Methods Study

    Dec 1, 2022, 00:00

  • PCR158 Patient Reported Outcomes (PRO) From Ongoing Phase 2 Registrational Trial of Repotrectinib in Patients With ROS1-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (TRIDENT-1)

    Dec 1, 2022, 00:00

  • EE412 HBA1C Point-of-Care Testing for Diabetes Control in Low-Income Remote Areas: A Cost-Parity Analysis

    Dec 1, 2022, 00:00

  • EPH17 Osteoporosis Screening in Community Pharmacies in Portugal

    Dec 1, 2022, 00:00

  • EPH25 Premature Mortality From Ischaemic Heart Disease Among Women in Hungary by District

    Dec 1, 2022, 00:00

  • CO108 Project Ideate: Designing a Robust Methodology for an Experimental, Retrospective Outcome-Based Agreement in a Breast Cancer Treatment

    Dec 1, 2022, 00:00

  • MSR121 Clinical Meaning of the Family-Reported Outcome Measure (FROM-16): A Novel Dimension of Real-World Data

    Dec 1, 2022, 00:00

  • PCR241 Measuring Preferences for Stroke Rehabilitation Using a Discrete Choice Experiment

    Dec 1, 2022, 00:00

  • MSR33 Application and Feasibility of Indirect Treatment Comparison of Switch Maintenance and Non-Maintenance Oncology Regimens to Inform HTA Decision-Making

    Dec 1, 2022, 00:00

  • HTA64 A Retrospective Review of NICE Appraisals From 2017-2022 to Investigate the Impact of the New Severity Modifier on Cost-Effectiveness Thresholds Across Multiple Therapy Areas

    Dec 1, 2022, 00:00

  • P22 Value of Information - Consolidated Health Economic Evaluation Reporting Standards: A Checklist Extension

    Dec 1, 2022, 00:00

  • EE35 Different Types of Innovative Models for Paying for Gene Therapies - Advantages and Possible Limitations

    Dec 1, 2022, 00:00

  • HTA263 Evaluation of the UK Innovative Licensing and Access Pathway

    Dec 1, 2022, 00:00

  • EE333 Evaluating the Long-Term Clinical, Societal, and Economic Outcomes of Ofatumumab vs Teriflunomide/Interferon Β-1A and the Impact of Early vs Delayed Ofatumumab Initiation in Relapsing Multiple Sclerosis Patients in Greece

    Dec 1, 2022, 00:00

  • EPH188 The Burden of Cancer Among Enrollees Insured Through Commercial Plans in the US (2019-2020)

    Dec 1, 2022, 00:00

  • EE559 The Economic Impact of Reducing Bleeding With Emicizumab in Patients With Hemophilia A and Factor VIII Inhibitors – Brazilian Case

    Dec 1, 2022, 00:00

  • P68 Investing in the Prevention of Infectious Disease Outbreaks: Fiscal Health Modelling for Assessing the Public Investment Case

    Dec 1, 2022, 00:00

  • EE225 What Is the Economic Impact of Delaying Kidney Replacement Therapy Through Ketoanalogue-Supplemented Low Protein Diet in Advanced Chronic Kidney Disease?

    Dec 1, 2022, 00:00

  • PCR196 Association of Clinical Response Criteria and Disease Activity Levels With Physical Function and HRQoL in Patients With Active Axial Spondyloarthritis: 16-Week Results From Two Phase 3 Randomised, Placebo-Controlled Studies

    Dec 1, 2022, 00:00

  • HTA8 The Catalan Health Service, An Example Where Patients Have Full Medicine Appraisal and Decision-Making Representation

    Dec 1, 2022, 00:00

  • HTA127 What Does the NICE Severity Modifier Mean in Reality? Has Cost Neutrality Restricted It Too Much?

    Dec 1, 2022, 00:00

  • PCR144 International Adaptation and Linguistic Validation of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ)

    Dec 1, 2022, 00:00

  • HPR146 What Are the Opportunities for Flat Pricing of Innovative Medicines Across the EU4 and UK?

    Dec 1, 2022, 00:00

  • PCR139 Qualitative Approaches Using Global Assessments to Support Meaningful Within-Person Change (MWPC) Estimates for Patient-Reported Outcome (PRO) Questionnaires in Regulated Clinical Trials

    Dec 1, 2022, 00:00

  • MT26 A Literature Review on Health Economic Evaluation of Pipeline Embolization Device (PED) in Treating Intracranial Aneurysms

    Dec 1, 2022, 00:00

  • MSR24 Can Artificial Intelligence Separate the Wheat From the Chaff in Systematic Reviews of Health Economic Papers?

    Dec 1, 2022, 00:00

  • EE354 Budget Impact Analysis of Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis in the UK

    Dec 1, 2022, 00:00

  • EE474 Budget Impact Analysis of Perioperative Nutrition in Surgical Oncology Patients

    Dec 1, 2022, 00:00

  • HSD100 A Multidisciplinary and Pharmacological Approach to the Treatment of Overweight and Obesity in a Health Maintenance Organization (HMO) in Brazil

    Dec 1, 2022, 00:00

  • HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective

    Dec 1, 2022, 00:00

  • CO141 Using LiveSLR Platform to Evaluate the Impact of Duration of Treatment (DOT) on Progression Free Survival (PFS) in Multiple Myeloma (MM)

    Dec 1, 2022, 00:00

  • HPR192 An Assessment of the Impact of the Three Memorandum Policies on Health Outcomes of the Greek Population

    Dec 1, 2022, 00:00

  • EE430 Cost-Effectiveness of Faricimab in Patients With Diabetic Macular Edema in Canada

    Dec 1, 2022, 00:00

  • PCR192 Treatment Burden and Its Relationship With Health-Related Quality of Life, Work Productivity and Activity Impairment in Adults With Severe Non-Inhibitor Hemophilia A in the United States: Data Analysis From the CHESS US+ Study

    Dec 1, 2022, 00:00

  • EE182 Budget Impact Analysis of Metabolic Surgery Compared With Best Medical Care for the Treatment of Comorbid Type 2 Diabetes and Obesity

    Dec 1, 2022, 00:00

  • PCR67 A Systematic Literature Review of Health-Related Quality of Life of Patients With Advanced Esophageal Cancer

    Dec 1, 2022, 00:00

  • EE117 Understanding the Expected Severity Modifiers Across Diseases Following Changes to NICE Methodology

    Dec 1, 2022, 00:00

  • SA7 Reduced Health Care Resource Utilisation and Costs Following a Switch From Multiple-Inhaler to Once-Daily Single-Inhaler Triple Therapy in COPD Patients in a Real-World Primary Care Setting in England

    Dec 1, 2022, 00:00

  • EPH203 Estimating the Impact of COVID-19 Pandemic on Gynaecology Treatment in England

    Dec 1, 2022, 00:00

  • EE16 Cost-Effectiveness of Cannabidiol Add-on Therapy Versus Placebo for the Treatment of Seizures in Tuberous Sclerosis Complex

    Dec 1, 2022, 00:00

  • EE459 Early Intensification of Oral Semaglutide in the UK: A Cost-Effectiveness Analysis Versus Continuing Metformin and SGLT-2 Inhibitor Therapy

    Dec 1, 2022, 00:00

  • HSD41 Development of 'Quality of Care for Patients With Advanced Illnesses (QCPAI)' Instrument for Measuring the Quality of End-of-Life Care From Patients’ Perspective

    Dec 1, 2022, 00:00

  • PCR244 Burden of Myelodysplastic Syndromes Part I: Systematic Literature Review of Epidemiologic and Humanistic Burden

    Dec 1, 2022, 00:00

  • SA77 Considerations for Patient Identification and Enrolment for Retrospective Studies for the Collection of Long-Term Follow-up Data

    Dec 1, 2022, 00:00

  • RWD50 Characteristics of Plaque Psoriasis Patients Initiating Biologics in the Real-World: Survey of Dermatology Practices Across the US and EU5 Countries

    Dec 1, 2022, 00:00

  • EE537 Cost-Effectiveness of Cemiplimab in Patients With Advanced Basal Cell Carcinoma (aBCC) Who Progressed on or Are Intolerant to a Hedgehog Inhibitor (HHI) in Italy

    Dec 1, 2022, 00:00

  • EE366 Healthcare Resource Consumption and Related Costs in Patients Under Antiretroviral Therapies: Findings From Real-World Data in Italy

    Dec 1, 2022, 00:00

  • HPR23 A Comparative Analysis of Biosimilar Competition in European Markets of TNF-Alpha Inhibitors

    Dec 1, 2022, 00:00

  • EPH13 Modelling the Impact on Lung Cancer Life Years of Universal Screening for Lung Cancer Amongst Defined High-Risk Populations in Greece

    Dec 1, 2022, 00:00

  • CO33 A Systematic Literature Review (SLR) of Comparative Efficacy Measures in Randomized Controlled Trials (RCTS) of Adjuvant Treatment in Localized Renal Cell Carcinoma (RCC)

    Dec 1, 2022, 00:00

  • EE114 Cost-Utility Analysis of Lung Cancer Screening Combined With Cardiovascular Disease and Chronic Obstructive Pulmonary Disease Screening

    Dec 1, 2022, 00:00

  • HTA50 The Architecture of Clinical Prediction Model Research: A Phased Approach

    Dec 1, 2022, 00:00

  • HTA9 The Benefits That a Novel Antimicrobial Provides When Viewed From an Insurance Value Perspective

    Dec 1, 2022, 00:00

  • EE362 Evaluating the Cost-Effectiveness of Refluxstop as a Treatment for Refractory Gastroesophageal Reflux Disease (GORD)

    Dec 1, 2022, 00:00

  • EE180 Budget Impact Model of Feiba in the Management of Hemophilia Patients With Inhibitors in the Egyptian Public Healthcare System

    Dec 1, 2022, 00:00

  • MSR115 Comparison of Statistical Models to Address Ceiling Effect in Utility Scores: A Simulation Study

    Dec 1, 2022, 00:00

  • HPR33 Price Erosion for Haemato-Oncology Drugs in European Markets

    Dec 1, 2022, 00:00

  • RWD53 Recurrence of Major Adverse Cardiovascular Events (MACE) in Patients Who Had a Prior Myocardial Infarction (MI): An Analysis Based on German Claims Data

    Dec 1, 2022, 00:00

  • EE639 Health Care Resource Utilization and Costs Among Persons With a Permanent or Temporary Stoma: A Swedish Register Study

    Dec 1, 2022, 00:00

  • CO101 Burden of Post-Stroke Spasticity: A Real-World Data Analysis in Italy

    Dec 1, 2022, 00:00

  • HPR35 Are the Sales Forecast for Medical Devices Accurate? A Retrospective Analysis in France (2018-2021)

    Dec 1, 2022, 00:00

  • SA72 Comparing EQ-5D-5L, Propr, Sf-6D and TTO Utilities in Patients With Chronic Skin Diseases

    Dec 1, 2022, 00:00

  • RWD160 Racial Disparity in the Treatment of Psoriasis in the US

    Dec 1, 2022, 00:00

  • PCR161 Being Active Is Not Enough – Combination of Physical Activity, Sedentary Behaviour and Sleep Characteristic Shows More Positive Effect on Infertility Related Quality of Life in Women Undergoing Art

    Dec 1, 2022, 00:00

  • HPR195 Assessing the Adoption of Sustainability Criteria Within National Healthcare Procurement Policies in Europe

    Dec 1, 2022, 00:00

  • EE21 Costs of Hemophilia in Ukraine

    Dec 1, 2022, 00:00

  • CO19 Adjunctive Albumin Infusion During Large-Volume Paracentesis May Improve Days to Next Hospital Readmission in Cirrhotic Patients

    Dec 1, 2022, 00:00

  • SA63 Communicating Complex Methodology Via Infographics: A MAIC Case Study

    Dec 1, 2022, 00:00

  • MSR77 Bayesian Hierarchical Model-Based Network Meta-Analysis to Overcome Survival Extrapolation Challenges Caused by Immature Data: Application in Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) PD-L1>1%

    Dec 1, 2022, 00:00

  • SA55 Literature Review and Meta Analysis of Alternative Autologous Vein in Below Knee Lower Limb Surgical Bypass in Patients With Critical Limb Ischemia Pad

    Dec 1, 2022, 00:00

  • HTA89 Androgen Receptor Inhibitors for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

    Dec 1, 2022, 00:00

  • EE610 Economic Investment for Saving a Year of Life Following the Israeli Government's Actions in the First Year of the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EE669 Use of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Spanish Hospital Setting: A Comparative Cost Analysis

    Dec 1, 2022, 00:00

  • EPH71 Factors Associating With the Severity of Soccer Injury Among Men and Women Professional Teams

    Dec 1, 2022, 00:00

  • CO65 Clinical and Economic Burden Among Patients With Prurigo Nodularis Compared to a Benchmark in Germany: A Real-World-Evidence Claims Data Study

    Dec 1, 2022, 00:00

  • MSR40 A Comparison of the Performance of a Range of Trial-Level Surrogacy Methods

    Dec 1, 2022, 00:00

  • EPH74 Mortality From Ischaemic Heart Disease Among Women in Hungary by County

    Dec 1, 2022, 00:00

  • HSD67 Real-World Effectiveness in Hypertension and Hyperlipidemia Collaborative Management Between Pharmacies and Primary Care in Portugal: A Multicenter Quasi-Experimental Pragmatic Controlled Trial (USFarmácia®)

    Dec 1, 2022, 00:00

  • EE629 Methodological Concerns in the Medico-Economic Modeling of Adjuvant Management

    Dec 1, 2022, 00:00

  • EE205 Cost-Effectiveness of Adherence Intervention for Tuberculosis Treatments in South Korea Using Discrete Event Simulation Model

    Dec 1, 2022, 00:00

  • CO66 Survival of Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib in France During 2009-2018: Potentialities and Limitations of Model Adjustment in the SNDS French Hospital and Claim Database

    Dec 1, 2022, 00:00

  • EPH53 The Role of Incentives- Parents’ Intention to Vaccinate Their 5- to 11-Year-Old Children with the COVID-19 Vaccine in Israel

    Dec 1, 2022, 00:00

  • PCR70 Avalglucosidase Alfa (AVA) Improves Symptoms and Functioning in Late-Onset Pompe Disease (LOPD) Patients vs Alglucosidase Alfa (ALG): Post-Hoc Analyses of Patient-Reported Outcomes (PROs) From COMET Trial

    Dec 1, 2022, 00:00

  • EE676 Impact of Using Innovative Antineoplastic Drugs on Cancer Mortality in Russia

    Dec 1, 2022, 00:00

  • HTA45 Uncertainty Regarding the Long-Term Effectiveness of New Therapies in Health Technology Assessment

    Dec 1, 2022, 00:00

  • EPH156 Treatment Patterns and Characteristics of People With Newly Diagnosed Major Depressive Disorder Across the Komodo Claims Database 2018-2020

    Dec 1, 2022, 00:00

  • EPH159 Creating an Online Patient Education Program for Female Population Who Are Over 50 Years Old

    Dec 1, 2022, 00:00

  • MSR80 Impact of Donor Ferritin Testing on Iron Deficiency Prevention and Blood Availability in Fran A Cohort Simulation Study

    Dec 1, 2022, 00:00

  • EE442 Care Costs of Non-Small Cell Lung Cancer, Colorectal Cancer, and Thyroid Cancer in Turkiye: A Delphi Panel Study

    Dec 1, 2022, 00:00

  • HTA110 The Value of Real-World Evidence (RWE) in Melanoma in Health Technology Assessment (HTA) Appraisals

    Dec 1, 2022, 00:00

  • EPH152 Ten-Year Epidemiology, Economic Burden and All-Cause Mortality Among Palmoplantar Pustolosis Patients: A 10-Year Canadian Prevalence Study of Inpatient Care, Emergency Departments, and Hospital- or Community-Based Outpatient Clinics

    Dec 1, 2022, 00:00

  • EE497 Healthcare Resource Utilization and Costs by Cardiovascular Risk Level: Results From the Latino Study

    Dec 1, 2022, 00:00

  • EE655 Potential Solutions for the Cost-Effectiveness Paradox of Improving Carer Quality-of-Life in Terminal Conditions

    Dec 1, 2022, 00:00

  • HPR141 Modelling the Impact of Pricing Exceptions and Protections on Pharmaceutical Expenditure in Greece

    Dec 1, 2022, 00:00

  • EE107 Ponesimod Indicated for Patients With Active Relapsing Forms of Multiple Sclerosis: A Budget Impact Analysis From the Italian National and Regional Health Care Service Perspective

    Dec 1, 2022, 00:00

  • EE339 Budget Impact Analysis of Insulin Glargine-300U/Ml (GLA-300) for Treatment of T1DM and T2DM in Algerian Setting

    Dec 1, 2022, 00:00

  • HTA156 Analysis of the Early Access Reform and Trends Observed in the Evaluation by the HAS

    Dec 1, 2022, 00:00

  • EE26 Costs of Illness of Atypical Hemolytic Uremic Syndrome (aHUS)

    Dec 1, 2022, 00:00

  • EE49 Cost-Effectiveness of Relmacabtagene Autoleucel (ANTI-CD19 AUTOLOGOUS CAR-T CELL IMMUNOTHERAPY PRODUCT) Vs Salvage Chemotherapy for Chinese Relapsed or Refractory Large B-Cell Lymphoma Patients

    Dec 1, 2022, 00:00

  • PCR18 An Exploratory Retrospective Social Listening Study to Identify Patient Experiences Associated With Cutaneous Lupus Erythematosus (CLE)

    Dec 1, 2022, 00:00

  • EE323 Cost-Utility Analysis of Polygenic Risk Score in the Prevention of Type 2 Diabetes – An Object-Oriented Individual-Level Model With Probabilistic Sensitivity Analysis

    Dec 1, 2022, 00:00

  • HTA120 National Health Technology Assessment in Turkey After a Decade: Are Key Principles Followed?

    Dec 1, 2022, 00:00

  • EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma

    Dec 1, 2022, 00:00

  • CO153 Mind-Body Modalities for Healthcare Workers in the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • HPR75 An Analysis of Special Pricing Arrangements (SPAS) Between 2013 and 2021 in Australia

    Dec 1, 2022, 00:00

  • EE429 Cost-Effectiveness and Budget Impact Analyses of Enzalutamide for the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer in Mexico

    Dec 1, 2022, 00:00

  • EE557 Cost-Effectiveness of Linaclotide Compared to Osmotic Laxatives in the Treatment of Irritable Bowel Syndrome With Constipation in China

    Dec 1, 2022, 00:00

  • RWD165 Impact of Armodafinil and Modafinil on Shift Work and Associated Metabolic Disorders

    Dec 1, 2022, 00:00

  • HSD103 Evolution 2019-2020 of Immune Checkpoint Inhibitors (ICI) Administration in Hospitalization at Home (HAH) for Cancer Patients in Fran Descriptive Analysis From the French Public Health Insurance Database (PMSI)

    Dec 1, 2022, 00:00

  • EE201 Survival Analysis Methods Used in Immuno-Oncology NICE Appraisals

    Dec 1, 2022, 00:00

  • PCR22 Measurement Properties of 15-Item Singapore Caregiver Quality of Life Scale (SCQOLS-15) in Family Caregivers of Patients With Heart Diseases

    Dec 1, 2022, 00:00

  • HTA245 NICE Immuno-Oncology Appraisals: Comparison of Progression-Free Survival and Overall Survival Analysis Methods and Critique

    Dec 1, 2022, 00:00

  • CO124 Indirect Comparison of Efficacy and Safety for Aumolertinib vs Osimertinib in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • HSD105 Cost Savings Benefits of Operational Waste Minimization in a Care Program by Cohorts of Babies on Treatment With Palivizumab

    Dec 1, 2022, 00:00

  • PCR87 Influence of Nutritional State and the Phase Angle in the Health Related Quality of Life and Clinical Outcome in Head and Neck Cancer

    Dec 1, 2022, 00:00

  • HTA86 Health Technology Assessment in Hospitals: A Systematic Review on Methods and Practices

    Dec 1, 2022, 00:00

  • HTA51 Challenges and Opportunities of Health Technology Assessment in Older Adult Immunization

    Dec 1, 2022, 00:00

  • CO62 Prophylaxis Treatment for Patients With Hemophilia A Without Inhibitors: Experience Monitoring Survey on the Use of Damoctocog Alfa Pegol

    Dec 1, 2022, 00:00

  • PCR198 Contemporary Trends in the Use of Generic Patient-Reported Outcome Measures in Pediatric Clinical Trials: An Analysis of Clinicaltrials.Gov

    Dec 1, 2022, 00:00

  • RWD11 Effectiveness Analysis of CPOE Implementation in Preventing Duplicate Medication: An Evidence From a Single Medical Center in Taiwan

    Dec 1, 2022, 00:00

  • Methodological Statistical Research

    Dec 1, 2022, 00:00

  • MSR81 Alternative Approaches to the Analysis of Utility Data: Atopic Dermatitis

    Dec 1, 2022, 00:00

  • EE386 Impact of Publication of the French Commission for Economic and Public Health Evaluation (CEESP) Doctrine on the Conclusions of Its Economic Opinions

    Dec 1, 2022, 00:00

  • Another Step Toward Hepatitis C Elimination: An Economic Evaluation of an Irish National Birth Cohort Testing Program

    Dec 1, 2022, 00:00

  • EE196 Updated Recommendations for Budget Impact Scale for HTA System Implementation in Ukraine

    Dec 1, 2022, 00:00

  • CO42 Efficacy and Safety of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors for Treatment of Anaemia of Chronic Kidney Disease: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE41 Healthcare Resource Utilization of Severe, Uncontrolled T2LOW and Non-T2LOW Asthma in Finland During 2018-2021

    Dec 1, 2022, 00:00

  • PCR223 Functional Class and Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease: Findings From a Real-World Study in the US

    Dec 1, 2022, 00:00

  • EE269 Evolution and Implications of the Portuguese HTA Framework on Health Economics in Patients’ Access to Innovation

    Dec 1, 2022, 00:00

  • EE411 Cost-Utility of Nabiximols for the Management of Spasticity Due to Multiple Sclerosis in Switzerland

    Dec 1, 2022, 00:00

  • RWD79 Burden of Hospitalization, Costs and Comorbidities in Medicaid Patients With Veno-Occlusive Disease (VOD): Analysis of National In-Patient Hospital Database

    Dec 1, 2022, 00:00
  • «
  • 21
  • 22
  • 23
  • 24
  • 25 (current)
  • 26
  • 27
  • 28
  • 29
  • 30
  • »